3 Or 4 Amino Acid Residues In The Peptide Chain Patents (Class 514/21.9)
-
Patent number: 8309513Abstract: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may be caused by or a cause of a variety of other conditions which are also encompassed by the present invention, such as viral and bacterial infections. Furthermore, the invention relates to a method for the treatment and/or prevention of compartment syndrome in a mammal in need thereof.Type: GrantFiled: October 27, 2008Date of Patent: November 13, 2012Assignee: Lantmannen As-Faktor ABInventors: Hans-Arne Hansson, Stefan Lange, Eva Jennische, Tomas Bergström
-
Patent number: 8304392Abstract: A peptide of formula: R1-X1-X2-X3-X4-X5-R2, wherein X1 is T; S2 is L; X3 is K; X4 is T, S, K, R or no amino acid; X5 is V, A, Y, M or no amino acid; R1 represents a primary amine function of the N-terminal amino acid; and R2 represents a hydroxyl function of the C-terminal amino acid, is capable of activating cytochrome C. The peptide can be included in cosmetic and pharmaceutical compositions intended to stimulate the functions of the mitochondria and increase intracellular ATP levels. Such compositions are useful to help protect the skin from external aggression, reduce and treat skin damage caused by UV radiation and combat cutaneous signs of aging.Type: GrantFiled: April 23, 2008Date of Patent: November 6, 2012Assignee: ISP Investments Inc.Inventors: Claude Dal Farra, Nouha Domloge, Jean-Marie Botto
-
Patent number: 8304393Abstract: It is intended to provide a novel oligopeptide which can be relatively easily produced, has not only a hair growth-stimulating effect but also an effect of promoting the growth of epithelial cells (for example, skin regeneration) and can easily pass through the horny layer to thereby reach the desired target cells in which its effects are to be exerted. Namely, water-soluble oligopeptides containing a proryl isoleucyl glycyl unit or an isoleucyl glycyl serine unit and having from 3 to 7 amino acids and water-soluble salts thereof.Type: GrantFiled: May 3, 2010Date of Patent: November 6, 2012Assignee: Patent Technology Development Inc.Inventors: Syuichi Oka, Akinori Tsuruda, Yasuhiro Kawano, Mitsuo Suzuki, Satoshi Nakazato
-
Publication number: 20120277164Abstract: Compounds based around tetrapeptide, tripeptide and dipeptide moeties and corresponding peptiod moeties. Related methods and pharmaceutical compositions for use in treatment of cancer, inflammatory diseases, and other disorders.Type: ApplicationFiled: October 22, 2010Publication date: November 1, 2012Applicant: Imperial Innovations LimitedInventors: Guido Franzoso, Albert Andrzej Jaxa-Chamiec, Caroline Minli Rachel Low, Simona Maria Monti, Menotti Ruvo, Laura Tornatore, Catherine Jane Tralau-Stewart
-
Publication number: 20120277167Abstract: Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.Type: ApplicationFiled: May 14, 2012Publication date: November 1, 2012Inventors: Jingyuan Wen, Gregory Brian Thomas, Mike John Bickerdike
-
Publication number: 20120270808Abstract: Embodiments of the invention include methods for selecting in parallel (i.e., synchronously or simultaneously) peptides that target a number of organs, in which each peptide targets distinct tissues or organs. Typically, the methods of the invention provide for peptide selection in a Minimal number of subjects and still provides a selectively binding peptide. In certain aspects, methods of identifying peptides that bind to multiple selected tissues or organs of an organism may comprise the steps of administering a phage display library to a first subject; obtaining a sample of two or more selected tissues; obtaining phage displaying peptides that bind to the samples from the first subject; enriching for peptides by administering phage isolated from the samples of the first subject to a second subject; obtaining a sample of two or more selected tissues from the second subject; and identifying the peptides displayed.Type: ApplicationFiled: April 4, 2012Publication date: October 25, 2012Inventors: Mikhail Kolonin, Wadih Arap, Renata Pasqualini
-
Publication number: 20120270795Abstract: The present invention relates to the field of protein misfolding diseases and thus to diseases which are associated with or induced by abnormal or pathogenic three-dimensional folding of proteins and/or peptides or which are linked to pathogenic conformational changes of proteins and/or peptides, such as Alzheimer's disease. Particularly, the present invention provides novel trimeric pyrazole compounds, which exhibit a therapeutic effectiveness in regard to the aforementioned protein misfolding diseases, and refers to their use for the treatment of such protein misfolding diseases, especially neurodegenerative diseases as well as to medicaments or pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: January 26, 2010Publication date: October 25, 2012Inventors: Thomas Schrader, Katrin Hochdörffer, Julia März-Berberich, Luitgard Nagel-Steger, Gal Bitan, Sharmistha Sinha
-
Publication number: 20120270811Abstract: A series of peptides with divergent confirmations including structures of formula (1A), (1B), (2) and (3) are provided. In the formula, wherein U, G, A, B, R1, R2 and T are as defined in the specification. The divergent peptides disclosed in the present invention are characterized in a mineral binding affinity function.Type: ApplicationFiled: October 21, 2011Publication date: October 25, 2012Applicant: KAOHSIUNG MEDICAL UNIVERSITYInventors: Hui-Ting Chen, Kuang-Chan Hsieh, Je-Ken Chang, Gwo-Jaw Wang, Yin-Chih Fu, Mei-Ling Ho, Cherng-Chyi Tzeng
-
Publication number: 20120270813Abstract: A process for producing a peptide product having cholecystokinin secretion promoting effect, said process comprising hydrolyzing soybean residues with one or more proteases so that the peptide product having cholecystokinin secretion promoting effect is obtained. Also disclosed is the composition containing the peptide product and the use thereof.Type: ApplicationFiled: October 5, 2011Publication date: October 25, 2012Applicant: Food Industry Research and Development InstituteInventors: Yi-Hong Chen, Yu-Hui Liu, Chu-Chin Chen, Shiao-Cheng Chuang, Hsiang-Ling Lai, Chien-Ti Chang, Ming-Yu Hung, Su-Er Liou, Fu-Ning Chien
-
Publication number: 20120264676Abstract: An antioxidant compound is disclosed, along with pharmaceutical compositions and methods of treatment which utilize said compound. The compound is characterized by a peptide including at least three amino acid residues of which at least two are cysteine residues, and a first hydrophobic or non-charged moiety being attached to an amino terminal of the peptide via a first bond and a second hydrophobic or non-charged moiety being attached to a carboxy terminal of the peptide via a second bond, as described herein. Cleavage of the peptide by an intracellular peptidase results in generation of a plurality of antioxidant species, each including one of the cysteine residues, thereby providing for a plurality of different antioxidant species acting in synergy in exerting antioxidation.Type: ApplicationFiled: April 25, 2012Publication date: October 18, 2012Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventor: Daphne ATLAS
-
Patent number: 8288341Abstract: Methods of treating radiation injury of a subject in need thereof comprising administering to the subject a peptide consisting of an amino acid molecule selected from the group consisting of VVC, LAG, AQG, LQGV, QVVC, MTRV, LAGV, LQAV, PGCP, VGQL, RVLQ, EMFQ, AVAL, FVLS, NMWD, LCFL, FSYA, FWVD, AFTV, LGTL, QLLG, YAIT, APSL, ITTL, QALG, GVLC, NLIN, SPIE, LNTI, LHNL, CPVQ, EVVR, MTEV, EALE, EPPE, LGTL, VGGI, RLPG, LQGA, LCFL, TLAVE, VEGNL, LNEAL, CPRGVNP, MGGTWA, LTCDDP, VCNYRDV, QPLAPLVG, and DINGFLPAL. The invention provides for administration of the peptide prior to and following exposure of the subject to a source of radiation.Type: GrantFiled: July 15, 2009Date of Patent: October 16, 2012Assignee: Biotempt B.V.Inventors: Robbert Benner, Nisar Ahmed Khan, Richard Michael Carlton
-
Publication number: 20120258909Abstract: The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant.Type: ApplicationFiled: June 9, 2011Publication date: October 11, 2012Applicant: ABBOTT LABORATORIESInventors: Bernd Liepold, Tina Jung, Peter Hölig, Rudolf Schroeder, Nancy E. Sever, Justin S. Lafountaine, Brent D. Sinclair, Yi Gao, Jianwei Wu
-
Publication number: 20120252734Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.Type: ApplicationFiled: June 15, 2012Publication date: October 4, 2012Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
-
Publication number: 20120252738Abstract: The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.Type: ApplicationFiled: November 12, 2010Publication date: October 4, 2012Applicant: R & D Biopharmaceuticals GmbHInventor: Wolfgang Richter
-
Publication number: 20120252739Abstract: The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.Type: ApplicationFiled: November 12, 2010Publication date: October 4, 2012Applicant: R&D Biopharmaceuticals GmbHInventor: Wolfgang Richter
-
Publication number: 20120244122Abstract: This invention relates to novel compounds that are peptides derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel peptides that are deuterated derivatives of boceprevir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating HCV infection.Type: ApplicationFiled: May 28, 2010Publication date: September 27, 2012Inventor: Craig E. Masse
-
Publication number: 20120245091Abstract: The present invention relates to a polypeptide derived from a highly conserved region (HCR) I-III of an extracellular region of a CD99 and CD99 family such as CD99L2 and PBDX (or XG), which are a kind of transmembrane protein, or a fused protein thereof. The polypeptide or the fused protein thereof has an activating function of inhibiting the extravasation of white blood cells, or inhibiting the growth and/or metastasis of cancer cells. The present invention also provides a polynucleotide coding the polypeptide, a vector including same, and a transformant transformed by the vector. In addition, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof for preventing or treating inflammatory diseases. Further, the present invention provides a pharmaceutical composition including the polypeptide or the fused protein thereof inhibiting the growth and/or metastasis of cancer cells, i.e., a pharmaceutical composition for preventing or treating cancer.Type: ApplicationFiled: August 24, 2010Publication date: September 27, 2012Applicant: SUPADELIXIR INC.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Sun-Hee Lee, Hyun-Mi Ju
-
Patent number: 8273716Abstract: The invention relates to methods of treatment or prophylaxis of physiological and/or pathological conditions with at least one LHRH antagonist, in particular at least one peptidomimetic LHRH antagonist such that the at least one LHRH antagonist is administered in a dose, which does not cause chemical (hormonal) castration.Type: GrantFiled: February 27, 2009Date of Patent: September 25, 2012Assignee: Spectrum Pharmaceuticals, Inc.Inventor: Juergen Engel
-
Publication number: 20120237552Abstract: Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK/JNK phosphorylation to various extents in both cell lines.Type: ApplicationFiled: August 31, 2010Publication date: September 20, 2012Inventors: Beatriz Moreno, Pablo Villoslada, Joaquin Messeguer, Gloria Navarro, Angel Messeguer
-
Publication number: 20120238503Abstract: The present invention relates to human laminin ?2 chain LG3 domain and active peptides promoting cell adhesion, spreading, migration, and neurite outgrowth. More particularly, it was found that when nerve cells are incubated using human laminin ?2 chain LG3 domain and active peptides in the LG3 domain, cell adhesion, spreading, migration, and neurite outgrowth of nerve cells promote and the promotion of cell adhesion, spreading, migration, and neurite outgrowth of nerve cells are integrin-mediated and achieved by the activation of PKC? and FAK phosphorylation. Thus, the present invention can be very useful for researches on cell adhesion, spreading, migration, and neurite outgrowth activities of cells which are focused on nerve cells and mediated by various extracellular matrix proteins including laminin, manufacture of artificial nerve conduits, burns treatment, wounds treatment, and tissue regeneration.Type: ApplicationFiled: March 12, 2012Publication date: September 20, 2012Applicant: SNU R&DB FOUNDATIONInventor: Byung-Moo MIN
-
Patent number: 8268789Abstract: Compounds represented by the general formula (1) or salts thereof or solvates of both; PAR-2 antagonists containing the compounds; and preventive or therapeutic agents for PAR-2 related diseases containing the antagonists as the active ingredient: (1) wherein R1 is hydrogen, halogeno, or a group represented by the general formula (2): (wherein R11 is straight-chain or branched C1-6 alkylene or the like; and R12 and R13 together with the nitrogen atom adjacent to them form a 5- to 7-membered ring); R2 is straight-chain or branched C1-6 alkyl or the like; R3 and R4 are each independently hydrogen, one to three halogen atoms, or the like; and A1-A2-A3 is a tripeptide residue composed of ?-amino acids each independently selected from the group consisting of glycine, alanine, cyclohexylalanine, and so on.Type: GrantFiled: September 30, 2005Date of Patent: September 18, 2012Assignee: Kowa Company, Ltd.Inventors: Mototsugu Kabeya, Kyoko Yasuoka, Toru Kanke, Hiroyuki Ishiwata, Junya Tagashira
-
Publication number: 20120225817Abstract: The present invention provides a therapeutic agent and a prophylactic agent for a gastrointestinal disease. A peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof promotes wound healing in a gastrointestinal mucosal tissue, and is therefore useful as a therapeutic agent or a prophylactic agent for a gastrointestinal disease. Further, when (a) a peptide having an amino acid sequence represented by Ser-Ser-Ser-Arg or a pharmaceutically acceptable salt thereof and (b) a peptide having an amino acid sequence represented by Phe-Gly-Leu-Met-NH2 or a pharmaceutically acceptable salt thereof are administered in combination, these medicaments act synergistically and can significantly promote wound healing in a gastrointestinal mucosal tissue.Type: ApplicationFiled: November 10, 2010Publication date: September 6, 2012Applicants: Santen Pharmaceutical Co., Ltd., Yamaguchi UniversityInventors: Teruo Nishida, Makoto Inui, Kenji Matsuura, Masatsugu Nakamura, Takashi Nagano
-
Publication number: 20120219498Abstract: An isolated peptide comprising an amino acid sequence HWRR as set forth by SEQ ID NO:5, the peptide consists of 4 or 5 amino acids, is provided. Also provided are methods of treating angiogenesis-related pathologies using the peptide of the invention or pharmaceutical compositions comprising same.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventors: BRITTA HARDY, ALEXANDER RATTLER, ANNAT RAITER, CHANA WEISS
-
Publication number: 20120219616Abstract: The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine.Type: ApplicationFiled: February 8, 2012Publication date: August 30, 2012Applicant: YOUR ENERGY SYSTEMS, LLCInventors: F. Timothy Guilford, Brian C. Keller
-
Publication number: 20120213790Abstract: The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.Type: ApplicationFiled: March 20, 2012Publication date: August 23, 2012Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: David M. Center, William W. Cruikshank, Hardy Kornfeld
-
Publication number: 20120214732Abstract: The present invention is an inhibitor of the trypsin-like ?2/?2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the ?2/?2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: Trustees of Dartmouth CollegeInventors: Alexei Kisselev, Dmitry V. Filippov, Herman Overkleeft
-
Publication number: 20120208771Abstract: Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity and mechanism for enhanced entry into cells. The configuration of the cholesterylamine-linker that is thought to provide for enhanced entry into cells includes a cholesterylamine that is coupled to a linker from the amine, and which linker includes a negative charge at a spatial distance from the amine of the cholesterylamine.Type: ApplicationFiled: August 12, 2010Publication date: August 16, 2012Applicants: THE PENN STATE RESEARCH FOUNDATION, UNIVERSITY OF KANSASInventor: Blake R. Peterson
-
Publication number: 20120207707Abstract: Methods of increasing production, stability or activity of a target polypeptide are provided herein. The method includes increasing the level of an antioxidant in a cell comprising a polynucleotide encoding the target polypeptide. Also provided are cells and transgenic organisms produced using the methods described herein. Methods of treating a subject with a condition treatable by administration of the target polypeptide are also disclosed. Finally methods and compositions for transiently increasing antioxidants in plant cells are provided.Type: ApplicationFiled: October 22, 2010Publication date: August 16, 2012Inventors: Maureen C. Dolan, Argelia Lorence, Giuliana Medrano
-
Publication number: 20120208748Abstract: The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome.Type: ApplicationFiled: February 10, 2012Publication date: August 16, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Yuqing E. Chen, Changyong Xue, Jifeng Zhang
-
Publication number: 20120202750Abstract: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4?, R5, R5?, R6 and R6? are as described herein.Type: ApplicationFiled: January 23, 2012Publication date: August 9, 2012Applicant: Genentech, Inc.Inventors: Frederick Cohen, Kurt Deshayes, Wayne J. Fairbrother, Bainian Feng, John A. Flygare, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui
-
Patent number: 8236766Abstract: The invention relates to synthetic peptide amides that are ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure: wherein Xaa is a D-amino acid and G is selected from the following three groups: The compounds are useful in the prophylaxis and treatment of pain, pruritus and inflammation associated with a variety of diseases and conditions.Type: GrantFiled: June 8, 2009Date of Patent: August 7, 2012Assignee: Cara Therapeutics, Inc.Inventors: Claudio D. Schteingart, Frederique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Zhiyong Luo
-
Patent number: 8236756Abstract: The present invention provides a new prodrug technology and new prodrugs in order to increase the solubility, to modulate plasma protein binding or to enhance the biovailability of a drug. In the present invention the prodrugs are conjugates of a therapeutic compound and a peptide (eg tetrapeptide or hexapeptide) wherein the conjugate is cleavable by dipeptidyl-peptidases, more preferably by CD26, also known as DPPIV (dipeptidyl aminodipeptidase IV). The present invention furthermore provides a method of producing the prodrugs, to enhance brain and lymphatic delivery of drugs and/or to extend drug half-lives in plasma.Type: GrantFiled: May 10, 2004Date of Patent: August 7, 2012Assignees: Consejo Superior de Investigaciones Clentificas (CSIC), K.U. Leuven Research & DevelopmentInventors: Jan Balzarini, Maria José Camarasa Ríus, Sonsoles Velázquez Díaz
-
Publication number: 20120196789Abstract: The present invention provides peptide-based peroxidase inhibitors having the formula AA1-AA2-AA3, wherein AA1 is a positively charged, negatively charged or neutral amino acid, AA2 is a redox active amino acid, and AA3 is an amino acid possessing a reducing potential such that AA3 is capable of undergoing a redox reaction with a radical of amino acid AA2 or a retro or retro-inverso analog thereof. The result of such a combination is a highly effective inhibitor of peroxidase activity that has potent anti-inflammatory properties in widely diverse models of vascular disease and injury. Exemplary tripeptides effectively inhibit peroxidase mediated LDL oxidation, increase vasodilation in SCD mice, inhibit eosinophil infiltration and collagen deposition in asthma mice, inhibit acute lung injury, and decrease ischemic injury of the heart.Type: ApplicationFiled: October 5, 2010Publication date: August 2, 2012Inventors: Hao Zhang, Yang Shi, Hao Xu, Kirkwood A. Pritchard, JR.
-
Publication number: 20120190614Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.Type: ApplicationFiled: April 10, 2012Publication date: July 26, 2012Applicant: AVILA THERAPEUTICS, INC.Inventors: Deqiang Niu, Russell C. Petter, Lixin Qiao, Juswinder Singh
-
Publication number: 20120183585Abstract: The various embodiments herein provide a gel based wound dressing comprising a lyophilized powder and a water-based solvent. The lyophilized powder comprises several nanoparticles and water miscible natural or synthetic polymers. The nanoparticles comprises pectin and a wound healing agent or an anti-microbial agent. The anti-microbial agent is nisin. The lyophilized powder and the water-based solvent are kept in two separate sealed packages and are mixed together before applying on a wound. The embodiments herein also provide a method of synthesizing the gel based wound dressing. The nano-particles control a release of the wound healing agent or the antimicrobial agent to a wound.Type: ApplicationFiled: February 25, 2012Publication date: July 19, 2012Inventors: Rassoul Dinarvand, Nasrin Samadi, Azade Taheri Borujeni
-
Patent number: 8222215Abstract: The present invention relates to compounds, pharmaceutical compositions containing such compounds and methods for their use. In particular, the compounds of the invention are useful for the treatment or prevention of diseases associated with T cell proliferation such as autoimmune diseases and disorders.Type: GrantFiled: September 5, 2008Date of Patent: July 17, 2012Assignee: Provid Pharmaceuticals, Inc.Inventors: Gary Lee Olson, Charles Michael Cook, Christopher Raymond Self
-
Publication number: 20120177667Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: March 23, 2012Publication date: July 12, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120177580Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: March 23, 2012Publication date: July 12, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Publication number: 20120177579Abstract: Compositions comprising a tripeptide having the sequence XC1C2; wherein X is any amino acid such that XC1C2 is capable of binding a metal in a square planar orientation or square pyramidal orientation or both; and wherein C1 and C2 are the same or different; and wherein C1 and C2 individually are chosen from a cysteine and a cysteine-like nonnatural amino acid, as well as metal-XC1C2 complexes and methods for forming such complexes.Type: ApplicationFiled: December 30, 2011Publication date: July 12, 2012Applicant: University of KansasInventors: Jennifer Ann Stowell Laurence, Anthony Andrew Vartia, Mary Elizabeth Krause
-
Patent number: 8217007Abstract: The invention relates to synthetic peptide amide ligands of the kappa opioid receptor and particularly to agonists of the kappa opioid receptor that exhibit low P450 CYP inhibition and low penetration into the brain. The synthetic peptide amides of the invention conform to the structure of formula I: Pharmaceutical compositions containing these compounds are useful in the prophylaxis and treatment of pain and inflammation associated with a variety of diseases and conditions. Such treatable pain includes visceral pain, neuropathic pain and hyperalgesia. Inflammation associated with conditions such as IBD and IBS, ocular and otic inflammation, other disorders and conditions such as pruritis, edema, hyponatremia, hypokalemia, ileus, tussis and glaucoma are treatable or preventable with the pharmaceutical compositions of the invention.Type: GrantFiled: May 25, 2010Date of Patent: July 10, 2012Assignee: Cara Therapeutics, Inc.Inventors: Claudio D. Schteingart, Frédérique Menzaghi, Guangcheng Jiang, Roberta Vezza Alexander, Javier Sueiras-Diaz, Robert H. Spencer, Derek T. Chalmers, Robert Zhiyong Luo
-
Patent number: 8217141Abstract: The present invention relates to the crystalline and amorphous structures of SEQ ID NO:1 (FLPS), methods of making the same and use in treatment of various diseases and conditions.Type: GrantFiled: May 19, 2008Date of Patent: July 10, 2012Assignee: Neopro Labs, LLCInventor: Hanna Skubatch
-
Patent number: 8217000Abstract: Methods for elevating and stabilizing prolactin levels in a mammal including methods of treating disorders and conditions associated with reduced serum levels of prolactin are provided. Also provided are methods of using certain synthetic tetrapeptide amides which are peripherally selective kappa opioid receptor agonists to elevate or stabilize serum prolactin levels.Type: GrantFiled: May 22, 2007Date of Patent: July 10, 2012Assignee: Cara Therapeutics, Inc.Inventors: Frederique Menzaghi, Michael E. Lewis, Derek T. Chalmers
-
Patent number: 8216998Abstract: The invention relates to the treatment of an ischemic event such as a stroke or myocardial infarction. The invention provides a method for modulating an ischemic event in a subject comprising providing the subject with a gene-regulatory peptide or functional analogue thereof. Furthermore, the invention provides use of an NF-?B-down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of reperfusion injury occurring after an ischemic event in a subject.Type: GrantFiled: November 6, 2006Date of Patent: July 10, 2012Assignee: Biotempt B.V.Inventors: Robbert Benner, Nisar Ahmed Khan, Bartholomeus Caspar J. Jacobs
-
Patent number: 8211637Abstract: The synthesis, biological evaluation, and molecular modeling of alkoxysuccinyl-peptidyl-haloalkyl ketones for use as proteinase K inhibitors are described. Sample preparation processes for in situ RNA or DNA analysis using such inhibitors, methods and compositions therefor are provided.Type: GrantFiled: December 18, 2009Date of Patent: July 3, 2012Assignee: Life Technologies CorporationInventors: Anilkumar R. Kore, Muthian Shanmugasundaram
-
Publication number: 20120165276Abstract: Disclosed are compounds having at least one quaternary alkyl ammonium functionality. The compounds inhibit bacterial efflux pump inhibitors and are used in combination with an anti-bacterial agent to treat or prevent bacterial infections. These combinations can be effective against bacterial infections that have developed resistance to anti-bacterial agents through an efflux pump mechanism.Type: ApplicationFiled: May 6, 2008Publication date: June 28, 2012Applicant: Mpex Pharmaceuticals, Inc.Inventors: TOMASZ GLINKA, Olga Lomovskaya, Keith Bostian, David M. Wallace
-
Publication number: 20120164072Abstract: Nano-sized particles are provided comprising at least one multi-headed amphiphilic compound, in which at least one headgroup of said multi-headed amphiphilic compound is selectively cleavable or contains a selectively cleavable group, and at least one biologically active agent, which is both encapsulated within the nano-particle and non-covalently associated thereto.Type: ApplicationFiled: May 4, 2010Publication date: June 28, 2012Inventors: Charles Linder, Sarina Grinberg, Eliahu Heldman
-
Patent number: 8207128Abstract: Described is a polypeptide inhibiting the transmigration of leukocytes or the growth and/or metastasis of cancer cells, a fusion protein thereof, a polynucleotide encoding the polypeptide, a vector including the polynucleotide, and a transformant transformed with the vector. Described is also a pharmaceutical composition for the prevention or treatment of inflammatory diseases, or the inhibition of the growth and/or metastasis of cancer cells including the polypeptide or a fusion protein thereof.Type: GrantFiled: September 20, 2006Date of Patent: June 26, 2012Assignee: Supadelixir Inc.Inventors: Jang-Hee Hahn, Kyoung-Jin Lee, Dong-Min Kang
-
Patent number: 8207131Abstract: The present invention relates to a peptide that is derived from a milk protein and has an antioxidative effect, an antioxidant that includes the peptide as an active ingredient, and an antioxidative food, drink, or feed that includes the peptide. The present invention also relates to a peptide that is derived from a milk protein and has an adiponectin production promotion effect, an adiponectin production promoter that includes the peptide as an active ingredient, and an adiponectin production promotion food, drink, or feed that includes the peptide. The present invention further relates to a blood adiponectin level increase promotion and/or decrease inhibition agent that includes a component contained in cheese as an active ingredient, and a blood adiponectin level increase promotion and/or decrease inhibition food or drink that includes a component contained in cheese.Type: GrantFiled: April 25, 2007Date of Patent: June 26, 2012Assignee: Megmilk Snow Brand Co., Ltd.Inventors: Yukiko Kunieda, Satoshi Higurashi, Mutsumi Motouri, Hiroaki Matsuyama, Atsushi Serizawa, Hiroshi Kawakami
-
Patent number: 8207125Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: GrantFiled: December 22, 2011Date of Patent: June 26, 2012Assignee: Onyx Therapeutics, Inc.Inventors: Mark S. Smyth, Guy J. Laidig
-
Patent number: 8207297Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.Type: GrantFiled: December 22, 2011Date of Patent: June 26, 2012Assignee: Onyx Therapeutics, Inc.Inventors: Mark S. Smyth, Guy J. Laidig